Interleukin 1 (IL 1) is a potent enhancer of nonspecific resistance to infection in mice. Since IL1 also induces interleukin 6 (IL6), we tested the hypothesis that IL 6 medi ates the effect of IL1 on nonspecific resistance. In a lethal Pseudomonas aeruginosa infection in granulocytopenic mice, in which 80 ng of recombinant human IL la pro tects against death, IL 6 appeared to be much less effective. Dosages of 8 ng, 80 ng and 320 ng IL 6 did not differ from the control, whereas 800 ng had a marginal protective effect (0.05 < p < 0.1). IL1 and IL 6 did not potentiate each other in ani mals treated with suboptimal dosages of both cytokines. Numbers of bacteria cultured from the blood, thigh muscle, liver, spleen, and kidney were similar in animals treated with 800 ng IL 6 and in control animals, arguing against activation of microbicidal mechanisms. The serum concentration profile of IL 6 after an i.p. injection of 80 ng IL1 was similar to that after 80 ng IL 6 i.p. Only minute amounts of IL1 were detected in serum after an i.p. injection of IL 6. Taken these data together, it appears that increased resistance to infection induced by IL1 is not mediated by IL 6.
I Introduction
Recently, we have reported the beneficial effect of recombi nant interleukin 1 (rIL 1) on survival of granulocytopenic mice with a lethal Pseudomonas aeruginosa infection [1] . In this study, we found protection with a single low dosage of IL1(3. Although we could demonstrate that protection was not due to a direct antimicrobial effect of IL 1, to granulocytes or to acti vation of macrophages, we were unable to elucidate the mechanisms of protection against lethal P. aeruginosa infec tion. One hypothesis was that treatment with IL1 protected against the lethal effects of the lipopolysaccharide (LPS) or other toxins of P. aeruginosa. In a subsequent study, in which the effect of IL 1 on a candidal infection in neutropenic mice was investigated, we could demonstrate that the effect of IL 1 on survival is not limited to Gram-negative infection [2] .
IL6 is a 26-kDa cytokine, which is produced by mononuclear phagocytes, fibroblasts and a variety of other types of cells ¡3-5]. This factor has been described as interferon-(32 [6] , hybridoma (plasmocytoma) growth factor [7] [8] [9] , B cellstimulating factor 2 (BSF-2) [10] and hepatocyte-stimulating factor [11] . Since IL1 is a potent inducer of IL 6, the latter could be responsible for the enhanced survival of animals treated with IL 1, e.g., by inducing a hepatic acute-phase pro tein. Therefore, we have compared the effects of IL 6 and IL 1 on survival of lethally infected mice. In addition, we have investigated the kinetics of injected IL 6 and IL1, and the mutual induction of these cytokines in vivo.
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Correspondence: Jos W. M. Van Female, 25 g Swiss Webster mice (Broekman, Someren, The Netherlands), were fed standard laboratory chow and water ad libitum.
IL
Human recombinant ILla (rILla), which was kindly pro vided by Dr. Peter Lomedico, Hoffmann-La Roche, Nutley, NJ, was used in the majority of the experiments. rIL 1(3 (kindly provided by Dr. Alan Shaw, Biogen/Glaxo, Geneva, Switzer land) was also used. These IL1 preparations contained <30 pg lipopolysaccharide (LPS) per mg of protein. Human rIL6, containing < 3 pg LPS/(ig of protein was produced as published elsewhere [8] .
IL1 and IL 6 were given as a single i.p. injection in 2% (v/v) normal mouse serum in 0.1 ml pyrogen-free saline. Control mice received heat-inactivated IL1 (100°C for 20 min).
Infection model
Mice were rendered granulocytopenic (<0.5 x 109 granulo cytes per liter) by means of two i.p. injections of cyclophos phamide (Bristol Myers, Syracuse, NY), 150 and 100 mg/kg of body weight, respectively, 4 days and 1 day before the inocu lation of the microorganism. Approximately 2 x 107 Pseudomonas aeruginosa (27853, ATCC, Rockville, MD) were injected into the left thigh muscle. Two doses of gentamycin (Lyomed Inc., Rosemont, IL), 120 mg/kg, were given s.c., 6 and 23 h post infection [1] . The mice in each cage were randomized to receive either IL 1, IL 6 or heat-inactivated IL 1, 24 h before the inoculation of bacteria. Survival was over a period of at least 48 h. Survival curves were analyzed using the Kaplan Meier log rank test [12] .
Clearance of bacteria
Twenty-four hours after the injection of P. aeruginosa, six mice treated with IL 6 and six control mice were killed by C 0 2 asphyxia. Immediately after death, blood cultures were taken by cardiac puncture, and the muscles of the left thigh (the site of inoculation of the bacteria), the spleen, the kidney and the liver were removed aseptically, weighed and homogenized in sterile saline in a tissue grinder. To bring the counts into the optimal range for reading, samples of thigh muscle were diluted 1 : 104 and other samples were diluted 1:10 in sterile saline. The suspensions were then plated on sterile DST agar (Oxoid, Ltd., Basingstoke, GB) in tenfold dilutions After overnight incubation at 37 °C the number of colonies was counted.
Pharmacokinetics of rIL 6 and rIL 1, and induction of IL 6 by IL 1
At various time points after an i.p. injection of 80 ng of IL 6, three mice were killed by C 0 2 asphyxia. Immediately after death blood was taken by cardiac puncture. The IL 6 concen trations in the sera obtained were measured using the B-9 cell line [5] , and IL1 concentrations were measured using D10.G4.1 cells [13] , the D10(N4)M subclone; both assays have been described in detail [14] . Similarly, serum concentra tions of IL 6 and IL 1 were measured after an i.p. injection of 80 ng IL la in mice. 
Survival of mice

Pharmacokinetics of rIL6 and induction of IL6 by IL1
The kinetics of 80 ng rIL 6 injected i.p. into mice (Fig. 4A) is remarkably similar to that of IL 6 induced by an i.p. injection of 80 ng rIL la (Fig. 4B ), although the maximal IL 6 concen tration after the IL 6 injection precedes that induced by IL1.
In contrast, the serum concentrations of IL 1 after injection of IL 6 are barely measurable (Fig. 4A) , whereas IL1 is readily measurable after injection of IL1 (Fig. 4B ).
Human rIL la, given as a single i.p. injection of 80 ng (~ 3 |ig/ kg) 24 h before infection, improved the survival of neu tropenic mice with a lethal P. aeruginosa infection significantly (X 2 = 6.8; p < 0 .01) compared to control mice that received heat-inactivated IL1 (Fig. 1 ). rIL 6 was much less effective than IL1 in these protection experiments (Fig. 1) . Even the effect of 800 ng IL 6 was not significantly different from the control (x2 = 3.0; 0.05 < p < 0.1); dosages of 320 ng, 80 ng and 8 ng did not differ from the control.
To investigate whether IL1 and IL 6 would potentiate each other, suboptimal dosages of both cytokines (8 ng and 80 ng, respectively) were injected either alone or in combination (Fig. 2) . No potentiation was detected; if anything, there was slight, albeit not significant antagonism between IL 1 and IL 6.
Clearance of P. aeruginosa
No differences in the numbers of bacteria in blood and tissues were found between mice treated with 800 ng IL 6 or control mice 24 h after an i.m. injection of 2 x 107 P. aeruginosa (Fig. 3) . When the data were expressed as number of microor ganisms per gram of tissue rather than per organ, the data from two groups also did not differ. ' : 
Discussion
In the present study, we have investigated the hypothesis that IL6 is the central mediator of IL 1-induced protection against lethal bacterial infection in mice. The experiments show that IL6 is 10-100 times less potent than IL 1 in protecting mice. If IL1 induced a large amount of IL 6 in vivo, these results still would not rule out an IL 6-mediated pathway. Although we could indeed demonstrate that IL 1 is a potent inducer of IL 6 in mice, the serum concentrations of IL 6 after an i.p. injection of 80 ng IL 1 are quite similar to those after an injection of the (barely protective) 80 ng dose of IL 6 i.p. Taking these data together, the hypothesis mentioned above has to be refuted.
The next question we addressed was whether IL1 and IL 6 would potentiate each other. Using suboptimal dosages of each cytokine, we could not detect any synergism. However, the 800-ng dose of IL 6 had some protective effect, and these results are reminiscent of experiments with tumor necrosis fac tor (TNF), in which a similar high dose was needed to find some protection [15, 16] . Since we observed that IL 6 does induce minute amounts to IL1 in vivo, the protection by IL 6 might be mediated via IL1.
The actual mechanism responsible for increase in survival induced by IL1, IL 6 and TNF remains unclear. In our previ ous studies direct antimicrobial effects of IL 1 were ruled out in vitro [1, 2\. Since the mice were profoundly granulocy topenic in those studies, an effect of IL 1 on the neutrophils was considered unlikely. Also, the beneficial effects of IL 1 on hematopoiesis [17] were not demonstrated in our short-term experiments [1, 2] . In the IL1 studies, no effect of IL1 on macrophages could be demonstrated [1] . The most convincing argument against an effect on microbicidal function of mac rophages, however, came from the microbial clearance data, which failed to demonstrate a difference between IL 1-treated and control mice [1, 2, 15] . In the present study, we have obtained similar results with IL 6, i.e., the numbers of bacteria in the blood and the various organs were similar in IL 1-treated mice and control mice.
It is assumed that cytokines like TNF and IL 1 contribute to death from infection [18] [19] [20] . It could well be that early treat ment with IL 1, and to a much lesser extent with IL 6, reduces the lethal effects of these cytokines. This protection could be produced by down-regulation of receptors for these cytokines in the lethal phase. The down-regulation of TNF receptors by IL 1 treatment, which has recently been described to occur in vitro, is in agreement with this concept [21] .
In conclusion, whatever the mechanisms of IL 1-induced pro tection against death due to lethal infection may be, IL 6 does not appear to be a critical intermediate cytokine.
